TEST:

Hedera Profiling 2 ctDNA test panel

"Hedera Dx...announces the publication of an analytical validation for a pan-cancer NGS liquid biopsy solution based on a unique decentralized and international multicenter study."

"Hedera Dx...announce that the Institute of Pathology at the Technical University of Munich (TUM) has successfully passed the QuIP proficiency test for the detection of ESR1 mutations in breast cancer patients using the Hedera Profiling 2 ctDNA Test Panel (HP2)."

All 4 approaches demonstrated S39 AMP Abstracts The Journal of Molecular Diagnostics â–  jmdjournal.orggood performance as proof of principle of their potential utility in liquid biopsy comprehensive or targeted genomic profiling. Detailed performance evaluation featured point s to consider, especially where VFs were near each method's limit of detection. An understanding of the strengths and weaknesses of each approach is essential to correctly interpret results.

"Hedera Dx...has unveiled a fully streamlined solution that allows hospitals to adopt liquid biopsy testing locally for their patients with minimal efforts. The solution is a combination of laboratory reagents and a software platform...The solution is called Hedera Profiling 2 ctDNA Test Panel and it integrates easily with the existing instrument infrastructure of a hospital lab. The test is built on actionability, in other words focusing on finding a potential treatment."